Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX05 vs Erbitux PK and Safety Study in Healthy Chinese Males
NCT06980454Phase 1Active, not recruiting
- Sponsor
- Henlius
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of HLX05 in metastatic colorectal cancer (mCRC) (4 arms), sponsored by Henlius. Primary endpoint: Area under the serum concentration-time curve from time 0 to infinity up to 29 days. Started Jun 2025; status: active, not recruiting.
02
Drugs
HLX05
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06980454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980454.